About The Doctor

 

Mark C. Glassy, Ph.D.

Dr. Glassy is the founder of Nascent Biotech. (www.nascentbiotech.com), the Director of and Professor at the Integrated Medical Science Association Foundation , and is on the faculty of the University of California, San Diego (UCSD) in the Mechanical and Aerospace Engineering Department and Bioscience Department.

In addition to UCSD, Dr. Glassy has held several upper management positions in commercial biotechnology. He was co-founder and CEO of Shantha West, Inc. a human antibody biomedical company associated with its parent, Shantha Biotechnics, of Hyderabad, India. He was also the CEO and founder of East/West Laboratories, Inc., the predecessor to Shantha West, Inc and prior to that served as Vice President of R&D for Novopharm Biotech, Inc. He has prepared and directed several FDA approved clinical trials involving human monoclonal antibodies to cancer. Prior to Novopharm, Dr. Glassy was Director of Immunology at Brunswick Biotechnetics and Chief, Human Antibody Program at Biotherapeutics, Inc.

Dr. Glassy joined the faculty of the Department of Medicine and Cancer Center at UCSD in 1980. He did his post-doctoral studies in molecular immunology at Scripps Clinic & Research Foundation, La Jolla and received his Ph.D. (summa cum laude) from the University of California, Riverside in 1978.

Dr. Glassy has over 160 publications in the scientific and medical literature, is the inventor of several issued patents in the human antibody field, is the Editor-in-Chief of the journal, HUMAN ANTIBODIES, and the Program Chairman of the meeting series, “The International Conference on Human Antibodies and Hybridomas”.

Glassy is the inventor of Pritumumab, the first human antibody used to treat a cancer patient. and is the recipient of the 2003 Arthur Furst Award. He is also the author of the book, “The Biology of Science Fiction Cinema”.